References
1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in
Wuhan, China: a descriptive study. The Lancet.2020;395(10223):507-513.
2. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al.
Clinical, laboratory and imaging features of COVID-19: A systematic
review and meta-analysis. Travel medicine and infectious disease.2020:101623.
3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ.
COVID-19: consider cytokine storm syndromes and immunosuppression.The Lancet. 2020;395(10229):1033-1034.
4. Eyi YE, Yetim M, Tekindur S. Endogenous and exogenous factors
affecting the levels of carboxyhemoglobin. The American journal of
emergency medicine. 2015;33(9):1310-1311.
5. Owens EO. Endogenous carbon monoxide production in disease.Clinical biochemistry. 2010;43(15):1183-1188.
6. Kakavas S, Papanikolaou A, Ballis E, Tatsis N, Goga C, Tatsis G.
Carboxyhemoglobin and methemoglobin levels as prognostic markers in
acute pulmonary embolism. The American journal of emergency
medicine. 2015;33(4):563-568.
7. Yasuda H, Yamaya M, Nakayama K, et al. Increased arterial
carboxyhemoglobin concentrations in chronic obstructive pulmonary
disease. American journal of respiratory and critical care
medicine. 2005;171(11):1246-1251.
8. Zegdi R, Perrin D, Burdin M, Boiteau R, Tenaillon A. Increased
endogenous carbon monoxide production in severe sepsis. Intensive
care medicine. 2002;28(6):793-796.
9. AKÇAY MŞ, Özlü T, Yilmaz A. Radiological approaches to COVID-19
pneumonia. Turkish Journal of Medical Sciences.2020;50(SI-1):604-610.
10. of the International CSG. The species Severe acute respiratory
syndrome-related coronavirus: classifying 2019-nCoV and naming it
SARS-CoV-2. Nature Microbiology. 2020:1.
11. Cunningham L, Kimber I, Basketter DA, McFadden JP. Why judiciously
timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.Autoimmunity Reviews. 2020.
12. Moore JB, June CH. Cytokine release syndrome in severe COVID-19.Science. 2020;368(6490):473-474.
13. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release
syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R)
antagonist Tocilizumab may be the key to reduce the mortality.International Journal of Antimicrobial Agents. 2020:105954.
14. Ryter SW, Kim HP, Nakahira K, Zuckerbraun BS, Morse D, Choi AM.
Protective functions of heme oxygenase-1 and carbon monoxide in the
respiratory system. Antioxidants & redox signaling.2007;9(12):2157-2174.
15. Kocak AO, Katipoglu B, Akbas I, Evrin T, Kasali K. Can
carboxyhemoglobin and total bilirubin be new prognostic indicators for
determining mortality in ischemic stroke? Kuwait Medical Journal.2019;51(4):356-361.